TWD 57.2
(-5.61%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 5.22 Million TWD | 1.2% |
2022 | 5.16 Million TWD | -3.62% |
2021 | 5.35 Million TWD | 11.07% |
2020 | 4.82 Million TWD | 24.71% |
2019 | 3.86 Million TWD | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q2 | 1.22 Million TWD | 11.22% |
2024 Q1 | 1.1 Million TWD | -32.87% |
2023 Q1 | 1.23 Million TWD | -26.95% |
2023 Q4 | 1.64 Million TWD | 59.96% |
2023 Q3 | 1.02 Million TWD | -21.81% |
2023 Q2 | 1.31 Million TWD | 6.47% |
2022 Q4 | 1.69 Million TWD | 0.0% |
2022 FY | 5.16 Million TWD | -3.62% |
2021 FY | 5.35 Million TWD | 11.07% |
2020 FY | 4.82 Million TWD | 24.71% |
2019 FY | 3.86 Million TWD | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
Apex Biotechnology Corp. | 531.11 Million TWD | 99.016% |
Sinphar Pharmaceutical Co.,Ltd. | 1.09 Billion TWD | 99.521% |
Panion & Bf Biotech Inc. | 912.56 Million TWD | 99.427% |
Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 757.3 Million TWD | 99.31% |
GenMont Biotech Incorporation | 177.33 Million TWD | 97.052% |
Abnova (Taiwan) Corporation | 173.91 Million TWD | 96.995% |
Adimmune Corporation | 410.93 Million TWD | 98.728% |
Tanvex BioPharma, Inc. | 59.7 Million TWD | 91.245% |
Polaris Group | -137.9 Million TWD | 103.79% |
UnicoCell Biomed Co., Ltd. | 17.89 Million TWD | 70.794% |
PELL Bio-Med Technology Co. Ltd. | -26.14 Million TWD | 119.996% |